Business
Santhera Licenses AGAMREE® (Vamorolone) to Nxera Pharma in Japan, South Korea, Australia and New Zealand in a Deal Valued at up to USD 205 Million Plus Royalties
Ad hoc announcement pursuant to Art. 53 LR Exclusive licensing agreement includes USD 40 million upfront comprising USD 30 million in cash and USD 10 million equity investment at CHF 14.91 per share, a 20% premium to the 30-day VWAP. Pratteln, Switzerland, January 8, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces it has signed an exclusive licensing agreement with Nxera Pharma UK Ltd. (“Nxera”) for the development, manufacturing and commercialization of AGAMREE® (vamorolone) for the treat
About this update from Santhera Pharmaceuticals Holding Ag
[{"type":"image","alt":"Santhera Pharmaceuticals Holding AG","displaySize":"","headline":null,"caption":"Santhera Pharmaceuticals Holding AG","className":"","disableSlideshowImg":false,"size":{"original":{"width":235,"height":71,"url":"https://media.zenfs.com/en/globenewswire.com/69b76b9d28605c9cb06e9f424ed2d9b3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/m.yMU32TDRiiNbpVl.Y_mw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/69b76b9d28605c9cb06e9f424ed2d9b3","width":235,"height":71}},"lazy":false},{"type":"text","content":"Ad hoc announcement pursuant to Art. 53 LR","length":42,"tagName":"p"},{"type":"text","content":"Exclusive licensing agreement includes USD 40 million upfront comprising USD 30 million in cash and USD 10 million equity investment at CHF 14.91 per share, a 20% premium to the 30-day VWAP.","length":190,"tagName":"p"},{"type":"text","content":"Pratteln, Switzerland, January 8, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces it has signed an exclusive licensing agreement with Nxera Pharma UK Ltd. (“Nxera”) for the development, manufacturing and commercialization of AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in Japan, South Korea, Australia and New Zealand. Nxera is a leading international biopharma company with clinical development and commercial operations for rare and speciality medicines in Japan and the broader Asia-Pacific (APAC) region.","length":547,"tagName":"p"},{"type":"text","content":"Under the terms of the agreement, Santhera will receive an upfront payment of USD 40 million from Nxera, consisting of USD 30 million in cash and USD 10 million as an equity investment in Santhera. The USD 10 million equity investment, through the purchase of c.530k shares, will be priced at CHF 14.91 per share, representing a 20% premium to the 30-day VWAP prior to the day of announcement. These shares will be issued shortly after closing of the agreement and will be subject to a customary lock up period. In addition, Santhera is eligible to receive up to USD 165 million in sales and regulatory milestone payments and will receive double-digit tiered royalties on net sales of AGAMREE in the licensed territories.","length":721,"tagName":"p"},{"type":"text","content":"Nxera will be responsible for securing regulatory approval for AGAMREE in the licensed ...